Akebia Therapeutics (AKBA) Tax Provisions (2018 - 2026)

Akebia Therapeutics (AKBA) posted quarterly Tax Provisions of $126000.0 for Q1 2026, down 87.51% quarter-over-quarter from $1.0 million in Q4 2025.

Akebia Therapeutics (AKBA) Tax Provisions (2018 - 2026) Analysis & Trends

Akebia Therapeutics (AKBA) has reported Tax Provisions for 4 consecutive years, with $126000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Tax Provisions changed N/A year-over-year to $126000.0; the TTM figure through Mar 2026 stood at $1.8 million (changed N/A YoY), while the FY2025 annual figure was $1.6 million, changed N/A from the prior year.
Tax Provisions fell to $126000.0 in Q1 2026 per AKBA's latest filing, from $1.0 million in the prior quarter.
Across five years, Tax Provisions topped out at $1.0 million in Q4 2025 and bottomed at $126000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Haleon	43.94 Bn	42.97 Bn	-	-
2	Teva Pharmaceutical Industries	42.95 Bn	39.30 Bn	2.15 Bn	121.00 Mn
3	Zoetis	31.58 Bn	29.90 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	-310.32 Mn
5	United Therapeutics	22.16 Bn	19.49 Bn	683.80 Mn	39.70 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn	54.80 Mn
7	Neurocrine Biosciences	15.53 Bn	15.14 Bn	935.80 Mn	17.80 Mn
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	2.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.95 Bn	-	-
10	Akebia Therapeutics	240.51 Mn	84.96 Mn	38.70 Mn	70,000.00

Download Data